Multi-Model Clinical Validation of an AI-Powered Biomarker Analysis Framework: A Cross-Vendor Benchmark on 4,018 NHANES Patients

This study demonstrates that a standardized prompt-based framework achieves clinical-grade accuracy across five large language models from four independent vendors when analyzing biomarkers from 4,018 NHANES patients, confirming the feasibility of vendor-independent AI systems for clinical decision support.

The Gist

Imagine you have a very important job: checking a patient's blood test results to see if they might have hidden health issues like diabetes, heart trouble, or liver problems. In the past, only human doctors could do this reliably. But now, we have "AI doctors" (Large Language Models) that can read these reports and spot patterns.

The big question was: Does it matter which AI doctor you hire? If you switch from one company's AI to another, will the diagnosis stay the same, or will the new AI get confused?

This paper is like a massive "blind taste test" for AI doctors. Here is how they did it, explained simply:

1. The Setup: The "Universal Menu"

Instead of asking each AI to "do its best," the researchers gave all of them the exact same recipe (a structured set of instructions, or "prompts"). They handed them the medical records of 4,018 real people from a national health survey (NHANES).

Think of it like a cooking competition where five different chefs (the AI models) are given the exact same ingredients and the exact same recipe card. The goal wasn't to see who could be the most creative, but to see who could follow the instructions most accurately to produce a perfect dish (a correct diagnosis).

2. The Contestants: The "Big Five"

They tested five different AI models from four different tech giants:

• Grok-3 (from xAI)
• GPT-4o & GPT-4o-mini (from OpenAI)
• Claude Haiku 4.5 (from Anthropic)
• Gemini 2.0 Flash (from Google)

Some of these were the "premium" models (the master chefs), and some were the "economy" models (the fast-food chefs).

3. The Challenge: Eight Health Patterns

The AIs had to look at blood numbers and decide if the patient had one of eight specific conditions, such as:

• Is their blood sugar too high? (Diabetes)
• Is their heart at risk?
• Do they have an iron deficiency? (Anemia)
• Is their liver struggling?

4. The Results: A Surprise Winner

The results were surprisingly good. All five AIs passed the test with flying colors. They all got scores high enough to be considered "clinical grade," meaning they were accurate enough to be trusted in a real hospital.

• The Champion: Grok-3 was the star of the show. It was almost perfect, getting a 100% score on liver risks and anemia. It was like a master chef who never burned a single dish.
• The Runners-Up: The other "premium" models (like GPT-4o) did very well, but the "economy" models (the cheaper, faster ones) were slightly less accurate. It's like the fast-food chef was still delicious, but the master chef was just a tiny bit more precise.
• The Hardest Dish: Predicting heart disease risk was the trickiest for everyone, like a soufflé that's hard to get right. Even the best AI struggled a bit more here than with the other conditions.

5. The Cost and The "Golden Ticket"

The whole experiment cost about $59 USD. That's less than a nice dinner for two!
The most important takeaway? The "recipe" (the framework) worked for everyone.

The Big Picture: Why This Matters

Imagine you are building a hospital. Before this study, you might have been scared to use an AI because you thought, "If I switch from Google's AI to OpenAI's AI, the diagnoses will change, and I'll have to retrain my whole system."

This paper proves that you don't need to worry. If you build a solid, standardized system (the recipe), you can swap out the AI "chefs" whenever you want without breaking the system. You can use the cheapest AI for routine checks and the most expensive one for complex cases, and the results will remain reliable.

In short: We found a universal translator for medical data. No matter which AI you talk to, if you ask the right question in the right way, they can all give you a trustworthy answer about your health.

Technical Summary

1. Problem Statement

While Large Language Models (LLMs) show significant promise for clinical decision support, current validation studies are limited by two critical gaps:

• Single-Model Bias: Most research evaluates only one specific model, failing to address whether clinical-grade performance is a property of the framework or specific to a single vendor's architecture.
• Generalizability & Vendor Dependence: There is a lack of evidence regarding whether a standardized clinical analysis framework can maintain accuracy across diverse models from independent providers (e.g., OpenAI, Anthropic, Google, xAI). This uncertainty hinders the deployment of robust, vendor-independent clinical AI systems.

2. Methodology

The study employed a rigorous, cross-vendor benchmarking approach to test the generalizability of a prompt-based clinical framework.

• Dataset: The evaluation utilized data from 4,018 adults drawn from the CDC's NHANES 2017-2018 cycle.
• Task Definition: The framework was designed to detect eight specific clinical patterns based on laboratory biomarkers:
  1. Insulin resistance
  2. Diabetes
  3. Cardiovascular disease (CVD) risk
  4. Chronic kidney disease (CKD) risk
  5. Systemic inflammation
  6. Nutrient deficiency
  7. Liver risk
  8. Anemia
• Models Evaluated: Five distinct LLMs from four major providers were tested using identical system prompts and input data:
  • xAI: Grok-3
  • OpenAI: GPT-4o and GPT-4o-mini
  • Anthropic: Claude Haiku 4.5
  • Google: Gemini 2.0 Flash
• Ground Truth: Clinical labels were established using strict, published clinical criteria from authoritative bodies: ADA (American Diabetes Association), AHA (American Heart Association), KDIGO (Kidney Disease: Improving Global Outcomes), and WHO.
• Evaluation Metrics: Performance was quantified using F1 scores (with 95% confidence intervals), sensitivity, specificity, positive predictive value (PPV), and JSON parse success rates.

3. Key Contributions

• Cross-Vendor Benchmarking: This is one of the first studies to systematically compare multiple LLMs from competing vendors on the same clinical task using a unified framework, moving beyond single-model validation.
• Model-Agnostic Framework Validation: The study demonstrates that a standardized prompt-based architecture can achieve clinical-grade accuracy regardless of the underlying model provider.
• Cost-Effectiveness Analysis: The research provides a concrete cost analysis, showing that high-volume clinical benchmarking can be achieved for a negligible cost (~$59 USD).
• Tiered Performance Analysis: It explicitly compares "flagship" models against "economy-tier" models, offering data-driven insights into the trade-offs between cost and clinical precision.

4. Key Results

• Overall Clinical-Grade Performance: All five models achieved an F1 score greater than 0.86, meeting the threshold for clinical-grade accuracy across all eight patterns.
• Performance Range:
  • Top Performer: Grok-3 achieved the highest mean F1 score of 0.963 (95% CI: 0.930–0.996).
  • Lowest Performer: GPT-4o-mini achieved a mean F1 of 0.865 (95% CI: 0.799–0.931), still within clinical-grade bounds.
• Flagship vs. Economy: Flagship models (Grok-3, GPT-4o, Claude Haiku 4.5) significantly outperformed economy-tier models (GPT-4o-mini, Gemini 2.0 Flash), with mean F1 scores of 0.940 vs. 0.881 (paired t-test, p=0.004).
• Pattern-Specific Insights:
  • High Accuracy: Grok-3 achieved near-perfect scores on Liver Risk (F1=1.000), Anemia (0.999), and Nutrient Deficiency (0.997).
  • Challenging Patterns: Cardiovascular disease risk was the most difficult pattern for all models, with F1 scores ranging from 0.853 to 0.885.
• Technical Reliability: JSON parse rates exceeded 99.9% for all models, indicating high structural reliability for integration into automated pipelines.

5. Significance and Implications

The study provides strong evidence that vendor-independent clinical AI systems are feasible. By demonstrating that a standardized framework maintains high accuracy across diverse models, the authors suggest that healthcare institutions can:

• Mitigate Vendor Lock-in: Deploy systems that can switch between models without requiring re-validation of the entire clinical framework.
• Optimize Costs: Leverage economy-tier models for less complex tasks or use a "router" architecture to balance cost and performance, knowing that even lower-tier models meet clinical standards.
• Enhance Robustness: Utilize ensemble methods or multi-model verification to increase confidence in clinical decision support, as the framework proves robust across different architectural paradigms.

In conclusion, the paper validates that LLMs, when guided by a structured, criteria-based prompt framework, can reliably translate raw laboratory data into clinically actionable insights across multiple commercial providers.